[18F]FDG-6-P as a novel in vivo tool for imaging staphylococcal infections

EJNMMI Research

Volumn 5, Issue 1, 2015, Pages 1-11

  Mills, Bethany ^a   Awais, Ramla O ^b   Luckett, Jeni ^a,b   Turton, Dave ^c   Williams, Paul ^a   Perkins, Alan C ^b   Hill, Philip J ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Infection diagnosis; NanoPET CT imaging; Pre clinical; S. aureus

Indexed keywords

FLUORODEOXYGLUCOSE F 18; FLUORODEOXYGLUCOSE F 18 6 PHOSPHATE; GLUCOSE; HEXOSE PHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; CELL CULTURE; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FOREIGN BODY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; MAMMAL CELL; MOLECULAR STABILITY; MOUSE; NONHUMAN; PET-CT SCANNER; PHOSPHORYLATION; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SIGNAL NOISE RATIO; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; SYNTHESIS; THIN LAYER CHROMATOGRAPHY; VALIDATION PROCESS;

EID: 84928678358     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/s13550-015-0095-1     Document Type: Article

References (45)

1. Dumarey N, Egrise D, Blocklet D, Stallenberg B, Remmelink M, del Marmol V, et al. Imaging infection with F-18-FDG-labeled leukocyte PET/CT: initial experience in 21 patients. J Nucl Med. 2006;47:625–32.
2. Signore A, Glaudemans AW. The molecular imaging approach to image infections and inflammation by nuclear medicine techniques. Ann Nucl Med. 2011;25:681–700. 10.1007/s12149-011-0521-z.
3. Palestro CJ, Love C, Bhargava KK. Labeled leukocyte imaging: current status and future directions. Q J Nucl Med Mol Imaging. 2009;53:105–23.
4. Kumar V. Radiolabeled white blood cells and direct targeting of micro-organisms for infection imaging. Q J Nucl Med Mol Imaging. 2005;49:325–38.
5. Basu S, Chryssikos T, Moghadam-Kia S, Zhuang H, Torigian DA, Alavi A. Positron emission tomography as a diagnostic tool in infection: present role and future possibilities. Semin Nucl Med. 2009;39:36–51.10.1053/j.semnuclmed.2008.08.004.
6. Love C, Palestro CJ. Radionuclide imaging of infection. J Nucl Med Technol. 2004;32:47–57. quiz 8–9.
7. Becker W, Meller J. The role of nuclear medicine in infection and inflammation. Lancet Infect Dis. 2001;1:326–33. 10.1016/S1473-3099(01)00146-3.
8. Wang Z, Ning X. Clinical diagnosis of bacterial infection via FDG-PET imaging. 2013.
9. Zoccali C, Teori G, Salducca N. The role of FDG-PET in distinguishing between septic and aseptic loosening in hip prosthesis: a review of literature. Int Orthop. 2009;33:1–5. 10.1007/s00264-008-0575-2.
10. Aksoy SY, Asa S, Ozhan M, Ocak M, Sager MS, Erkan ME, et al. FDG and FDG-labelled leucocyte PET/CT in the imaging of prosthetic joint infection. Eur J Nucl Med Mol Imaging. 2014;41:556–64. 10.1007/s00259-013-2597-2.
11. Stumpe KD, Dazzi H, Schaffner A, von Schulthess GK. Infection imaging using whole-body FDG-PET. Eur J Nucl Med. 2000;27:822–32.
12. Chacko TK, Zhuang H, Nakhoda KZ, Moussavian B, Alavi A. Applications of fluorodeoxyglucose positron emission tomography in the diagnosis of infection. Nucl Med Commun. 2003;24:615–24. 10.1097/01.mnm.0000075189.60210.df.
13. Rosenbaum SJ, Lind T, Antoch G, Bockisch A. False-positive FDG PET uptake–the role of PET/CT. Eur Radiol. 2006;16:1054–65. 10.1007/s00330-005-0088-y.
14. Moberg L, Karawajczyk M, Venge P. 99mTc-HMPAO (Ceretec) is stored in and released from the granules of eosinophil granulocytes. Br J Haematol. 2001;114:185–90. 10.1046/j.1365-2141.2001.02889.x.
15. Lukawska JJ, Livieratos L, Sawyer BM, Lee T, O’Doherty M, Blower PJ, et al. Real-time differential tracking of human neutrophil and eosinophil migration in vivo. J Allergy Clin Immunol. 2014;133:233–9. e1.10.1016/j.jaci.2013.06.031.
16. Bunschoten A, Welling MM, Termaat MF, Sathekge M, van Leeuwen FW. Development and prospects of dedicated tracers for the molecular imaging of bacterial infections. Bioconjug Chem. 2013;24:1971–89.10.1021/bc4003037.
17. Sasser TA, Van Avermaete AE, White A, Chapman S, Johnson JR, Van Avermaete T, et al. Bacterial infection probes and imaging strategies in clinical nuclear medicine and preclinical molecular imaging. Curr Top Med Chem. 2013;13:479–87. CTMC-EPUB-20130207-8.
18. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev. 1997;10:505–20.
19. Dall’Antonia M, Coen PG, Wilks M, Whiley A, Millar M. Competition between methicillin-sensitive and -resistant Staphylococcus aureus in the anterior nares. J Hosp Infect. 2005;61:62–7. 10.1016/j.jhin.2005.01.008.
20. ECDC. Antimicrobial resistance surveillance in Europe 2011. Eur Centre Dis Prev Control. 2012;1:55–7.
21. ECDC. Antimicrobial resistance surveillance in Europe 2012. Eur Centre Dis Prev Control. 2013;1:59–62.
22. Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998;339:520–32. 10.1056/NEJM199808203390806.
23. WHO. Antimicrobial resistance: global report on surveillance 2014. WHO. 2014;1:9–12. 19–21.
24. Beceiro A, Tomás M, Bou G. Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world? Clin Microbiol Rev. 2013;26:185–230. 10.1128/cmr. 00059-12.
25. Gorak EJ, Yamada SM, Brown JD. Community-acquired methicillin-resistant Staphylococcus aureus in hospitalized adults and children without known risk factors. Clin Infect Dis. 1999;29:797–800. 10.1086/520437.
26. Charlebois ED, Bangsberg DR, Moss NJ, Moore MR, Moss AR, Chambers HF, et al. Population-based community prevalence of methicillin-resistant Staphylococcus aureus in the urban poor of San Francisco. Clin Infect Dis. 2002;34:425–33. 10.1086/338069.
27. Carleton HA, Diep BA, Charlebois ED, Sensabaugh GF, Perdreau-Remington F. Community-adapted methicillin-resistant Staphylococcus aureus (MRSA): population dynamics of an expanding community reservoir of MRSA. J Infect Dis. 2004;190:1730–8. 10.1086/425019.
28. Diederen BM, Kluytmans JA. The emergence of infections with community-associated methicillin resistant Staphylococcus aureus. J Infect. 2006;52:157–68. 10.1016/j.jinf.2005.09.001.
29. Kluytmans-Vandenbergh MF, Kluytmans JA. Community-acquired methicillin-resistant Staphylococcus aureus: current perspectives. Clin Microbiol Infect. 2006;12 Suppl 1:9–15. 10.1111/j.1469-0691.2006.01341.x.
30. Winkler HH. Distribution of an inducible hexose-phosphate transport-system among various bacteria. J Bacteriol. 1973;116:1079–81.
31. Kaarstad K, Bender D, Bentzen L, Munk OL, Keiding S. Metabolic fate of 18F-FDG in mice bearing either SCCVII squamous cell carcinoma or C3H mammary carcinoma. J Nucl Med. 2002;43:940–7.
32. Kuklin NA, Pancari GD, Tobery TW, Cope L, Jackson J, Gill C, et al. Real-time monitoring of bacterial infection in vivo: development of bioluminescent staphylococcal foreign-body and deep-thigh-wound mouse infection models. Antimicrob Agents Chemother. 2003;47:2740–8.
33. Hook AL, Chang CY, Yang J, Luckett J, Cockayne A, Atkinson S, et al. Combinatorial discovery of polymers resistant to bacterial attachment. Nat Biotechnol. 2012;30:868–75. 10.1038/nbt.2316.
34. 18F]-fluoromaltose as a novel PET tracer for imaging bacterial infection. PLoS One. 2014;9:e107951. 10.1371/journal.pone.0107951 PONE-D-14-25942.
35. Weinstein EA, Ordonez AA, DeMarco VP, Murawski AM, Pokkali S, MacDonald EM, et al. Imaging Enterobacteriaceae infection in vivo with 18F-fluorodeoxysorbitol positron emission tomography. Sci Transl Med. 2014;6:259ra146. 10.1126/scitranslmed.3009815.
36. Archer NK, Mazaitis MJ, Costerton JW, Leid JG, Powers ME, Shirtliff ME. Staphylococcus aureus biofilms: properties, regulation, and roles in human disease. Virulence. 2011;2:445–59. 10.4161/viru.2.5.17724.
37. Yarwood JM, Bartels DJ, Volper EM, Greenberg EP. Quorum sensing in Staphylococcus aureus biofilms. J Bacteriol. 2004;186:1838–50.
38. Etzioni DA, Liu JH, Maggard MA, Ko CY. The aging population and its impact on the surgery workforce. Ann Surg. 2003;238:170–7.10.1097/01.SLA.0000081085.98792.3d 00000658-200308000-00003.
39. Thurlow LR, Hanke ML, Fritz T, Angle A, Aldrich A, Williams SH, et al. Staphylococcus aureus biofilms prevent macrophage phagocytosis and attenuate inflammation in vivo. J Immunol. 2011;186:6585–96. jimmunol.1002794.
40. Kadurugamuwa JL, Sin LV, Yu J, Francis KP, Purchio TF, Contag PR. Noninvasive optical imaging method to evaluate postantibiotic effects on biofilm infection in vivo. Antimicrob Agents Chemother. 2004;48:2283–7. 10.1128/AAC.48.6.2283-2287.2004 48/6/2283.
41. Fueger BJ, Czernin J, Hildebrandt I, Tran C, Halpern BS, Stout D, et al. Impact of animal handling on the results of 18F-FDG PET studies in mice. J Nucl Med. 2006;47:999–1006. 47/6/999.
42. Kim C, Kim IH, Kim SI, Kim YS, Kang SH, Moon SH, et al. Comparison of the Intraperitoneal, retroorbital and per oral routes for F-18 FDG administration as effective alternatives to intravenous administration in mouse tumor models using small animal PET/CT studies. Nucl Med Mol Imaging. 2011;45:169–76.10.1007/s13139-011-0087-7 87.
43. Watanabe M, Goto H, Matsushima M, Shimono R, Kihara T. Distribution of glucose-6-phosphatase activity in mice studied by in vitro whole-body autoradiography. J Histochem Cytochem. 1983;31:1426–9.
44. Burns RL, Rosenberger PG, Klebe RJ. Carbohydrate preferences of mammalian cells. J Cell Physiol. 1976;88:307–16.10.1002/jcp.1040880306.
45. Jamar F, Buscombe J, Chiti A, Christian PE, Delbeke D, Donohoe KJ, et al. EANM/SNMMI guideline for 18F-FDG use in inflammation and infection. J Nucl Med. 2013;54:647–58. 10.2967/jnumed.112.112524.